When a phase 3 result is announced, the first number to travel is usually the biggest one. For survodutide, an investigational once-weekly injection from Boehringer Ingelheim, two different numbers have been in circulation: about 16.6% average weight loss in the company’s topline announcement, and 12–13% in the peer-reviewed paper. Both come from the same trial. The gap between them is a useful lesson in how to read these results.
What the trial found
SYNCHRONIZE-1 was a 76-week, randomized, double-blind, placebo-controlled phase 3 trial published in the New England Journal of Medicine. It enrolled 725 adults with obesity, or with overweight plus at least one weight-related complication, at 116 sites in 14 countries. People with diabetes were excluded. Everyone, including the placebo group, received lifestyle counseling. Survodutide activates two hormone receptors, GLP-1 and glucagon.
Participants were randomized to a dose titrated up to 3.6 mg, a dose titrated up to 6.0 mg, or placebo. In the paper’s primary analysis, average weight change at 76 weeks was:
- Placebo — about 5%
- Survodutide 3.6 mg — about 12%
- Survodutide 6.0 mg — about 13%
The share of participants who lost at least 5% of body weight was 73% and 72% on the two survodutide doses versus 46% on placebo.
The average participant was 47 years old, 41% were men, 68% were White, and the average starting BMI was 37.9.
Why 16.6% and 12–13% are both “correct”
The sponsor’s topline announcement led with 16.6%, which came from an efficacy estimand: what the drug does if everyone stays on it as directed. The NEJM paper’s primary analysis used a treatment-regimen estimand, which counts people as randomized even if they stopped the drug, started a prohibited weight medication, or had a long dose-escalation period.
Neither is dishonest. They answer different questions:
- Efficacy estimand: how well does the drug work in people who keep taking it?
- Treatment-regimen estimand: what happens across everyone who is offered it, including people who stop?
The second is closer to what a real-world population experiences, and it is the more conservative number. If a figure is quoted without saying which one, you cannot tell what it means.
The tolerability picture
Gastrointestinal symptoms were the most common side effects and were mostly mild to moderate. They were reported by 81% of participants on 3.6 mg and 90% on 6.0 mg, versus 48% on placebo. No deaths were reported. The authors describe the safety profile as consistent with other medications that act on the GLP-1 receptor.
The authors also acknowledge a “substantial” share of participants discontinued the trial regimen. That detail matters: it is part of why the treatment-regimen number is lower than the efficacy number, and one reason a trial average is a poor forecast of any single person’s experience.
What the trial does not establish
- It does not compare survodutide with anything else. There was no active comparator. Lining its result up beside results from other trials is tempting but unreliable, because populations, durations, doses, and analysis methods differ.
- It does not describe people with type 2 diabetes. Separate studies cover that group.
- It does not describe who was left out. People with uncontrolled hypertension were excluded, so the results may not generalize to everyone with obesity.
- It says little about the long term. Seventy-six weeks does not answer what happens over years, or after stopping.
- It is not an approved treatment. Survodutide is investigational, and regulators will judge it on the full data package.
Where this leaves compounded medications
Survodutide is not among the medications NoBsRx provides, so this is not a product pitch. But the boundary shapes how to read everything else in this field.
Every result above belongs to one manufacturer’s investigational product, made and studied under a formal protocol. Nothing in it transfers to any other preparation. The same is true of the semaglutide and tirzepatide trials people often cite: they studied the branded manufactured products. Compounded semaglutide and tirzepatide are prepared by state-licensed pharmacies for individual patients, are not FDA-approved, and have not been through those trials. A product sold online under the name of an investigational drug has not been through this trial either, whatever the advertising implies.
The reasonable takeaway is narrow: the science of this drug class keeps moving, and a large trial average is a reason to be curious, not a reason to expect a particular outcome. If you are weighing a treatment, the useful questions are the ones a licensed provider asks about your history, your other conditions, and your goals. Our FAQ and how it works pages describe what that review looks like.
This post is general information, not medical advice. It does not describe a benefit of any NoBsRx program and is not a claim that any medication will produce a particular result. Compounded medications are not FDA-approved. Treatment is never guaranteed — eligibility and every treatment decision are made by independent licensed providers based on an individual clinical assessment, and availability varies by state. Do not start, stop, or change any medication based on an article. Talk to a licensed clinician about your own situation.